Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM.

J Pharmacol Exp Ther. 2012 Nov;343(2):509-19. doi: 10.1124/jpet.112.196097. Epub 2012 Aug 6.

PMID:
22869928
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.

Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG.

Cancer Res. 2010 Dec 15;70(24):10090-100. doi: 10.1158/0008-5472.CAN-10-0489. Epub 2010 Oct 15.

PMID:
20952508
[PubMed - indexed for MEDLINE]
Free Article
3.

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

Zhou Q, Guo P, Gallo JM.

Clin Cancer Res. 2008 Mar 1;14(5):1540-9. doi: 10.1158/1078-0432.CCR-07-4544. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308-9.

PMID:
18316579
[PubMed - indexed for MEDLINE]
Free Article
4.

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.

Zhou Q, Gallo JM.

Neuro Oncol. 2009 Jun;11(3):301-10. doi: 10.1215/15228517-2008-088. Epub 2008 Oct 29.

PMID:
18971416
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

PMID:
19417025
[PubMed - indexed for MEDLINE]
Free Article
6.

Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.

Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, Filetti S, Russo D, Durante C.

Oncol Rep. 2011 Nov;26(5):1075-80. doi: 10.3892/or.2011.1422. Epub 2011 Aug 17.

PMID:
21850379
[PubMed - indexed for MEDLINE]
7.

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B.

Neuro Oncol. 2010 Aug;12(8):822-33. doi: 10.1093/neuonc/noq017. Epub 2010 Feb 23.

PMID:
20179017
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.

de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS.

Neuro Oncol. 2007 Oct;9(4):412-23. Epub 2007 Jul 10.

PMID:
17622648
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1053-62. doi: 10.1158/0008-5472.CAN-09-3722. Epub 2010 Jan 26.

PMID:
20103629
[PubMed - indexed for MEDLINE]
Free Article
10.

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R.

Mol Cancer Ther. 2010 Jun;9(6):1525-35. doi: 10.1158/1535-7163.MCT-09-1106. Epub 2010 May 25.

PMID:
20501804
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM.

Neoplasia. 2009 Sep;11(9):910-20.

PMID:
19724685
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.

Jing C, Ning J, Yuanjie N.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2137-43. doi: 10.1007/s00432-012-1295-y. Epub 2012 Aug 7.

PMID:
22868821
[PubMed - indexed for MEDLINE]
13.

Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.

Su SC, Hu X, Kenney PA, Merrill MM, Babaian KN, Zhang XY, Maity T, Yang SF, Lin X, Wood CG.

Clin Cancer Res. 2013 Dec 1;19(23):6461-72. doi: 10.1158/1078-0432.CCR-13-1284. Epub 2013 Oct 11.

PMID:
24122794
[PubMed - indexed for MEDLINE]
14.

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1063-71. doi: 10.1158/0008-5472.CAN-09-3965. Epub 2010 Jan 26.

PMID:
20103651
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.

Sakai I, Miyake H, Fujisawa M.

BJU Int. 2013 Jul;112(2):E211-20. doi: 10.1111/j.1464-410X.2012.11655.x. Epub 2013 Jan 10.

PMID:
23305097
[PubMed - indexed for MEDLINE]
16.

Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.

Gaustad JV, Simonsen TG, Leinaas MN, Rofstad EK.

BMC Cancer. 2012 Sep 4;12:388. doi: 10.1186/1471-2407-12-388.

PMID:
22947392
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.

Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S.

Neoplasia. 2009 May;11(5):426-35.

PMID:
19412427
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.

Cancer Res. 2000 Aug 1;60(15):4152-60.

PMID:
10945623
[PubMed - indexed for MEDLINE]
Free Article
19.

Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.

Broutin S, Ameur N, Lacroix L, Robert T, Petit B, Oumata N, Talbot M, Caillou B, Schlumberger M, Dupuy C, Bidart JM.

Clin Cancer Res. 2011 Apr 1;17(7):2044-54. doi: 10.1158/1078-0432.CCR-10-2041. Epub 2011 Feb 15.

PMID:
21325074
[PubMed - indexed for MEDLINE]
Free Article
20.

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.

Sablin MP, Dreyer C, Colichi C, Bouattour M, Delbaldo C, Faivre S, Raymond E.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1005-15. doi: 10.1517/17425255.2010.506872. Review.

PMID:
20636223
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk